A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Recruiting now · Phase 2
Conditions studied: Neuroblastoma, Sarcoma
In brief
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted. The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors with minimal disease burden, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors and thereby significantly extend the period of disease control and/or induce a durable cure.
Key facts
- Study ID
- NCT05135975
- Run by
- Nationwide Children's Hospital
- People needed
- 86
- Starts
- 2022-07-20
- Expected to finish
- 2029-12-01
- Last updated by the study team
- 2025-08-12
Who can join
Age: 2 and older, up to 40. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital of Alabama/UAB — Birmingham, Alabama, United States (enrolling)
- Children's Hospital of Colorado — Aurora, Colorado, United States (enrolling)
- Children's National Medical Center — Washington D.C., District of Columbia, United States (enrolling)
- Children's Hospital at Montefiore — The Bronx, New York, United States (enrolling)
- Nationwide Children's Hospital — Columbus, Ohio, United States (enrolling)
- Primary Children's Hospital — Salt Lake City, Utah, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.